Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 10/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918738 | 0.81 | ALDH1A1 (0.46) | MGLLKDM4EGAAALDH1A1NTRK1 | |
| SCHEMBL17255733 | 0.81 | KDM4E (0.47) | KDM4EGAAALDH1A1NTRK1LMNA | |
| SCHEMBL1814517 | 0.80 | CYP1A2 (0.57) | P2RY1OPRM1ALDH1A1LMNA | |
| SCHEMBL31457163 | 0.80 | CYP1A2 (0.57) | P2RY1OPRM1ALDH1A1LMNA | |
| SCHEMBL15428744 | 0.78 | P2RY1 (0.46) | P2RY1ALDH1A1LMNA | |
| SCHEMBL4917405 | 0.78 | KDM4E (0.50) | P2RY1KDM4EOPRM1GAAALDH1A1 | |
| SCHEMBL15442119 | 0.75 | KCNN4 (0.44) | P2RY1MGLLKDM4EGAAALDH1A1 | |
| SCHEMBL200831 | 0.74 | MAPK1 (0.63) | KDM4EGAAALDH1A1NTRK1LMNA | |
| SCHEMBL23402247 | 0.72 | ALDH1A1 (0.42) | MGLLKDM4EOPRM1ALDH1A1 | |
| SCHEMBL14473680 | 0.71 | KMT2A (0.47) | GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008023235-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | P2RY1, P2RY11, P2RX7 | P2RY1 1/4885MGLL 4410/4885KDM4E 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.